Related Experiment Video

Updated: Jun 29, 2025

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.6K

RedOx regulation of LRRK2 kinase activity by active site cysteines

Chiara R Trilling1, Jui-Hung Weng2, Pallavi Kaila Sharma2

  • 1Department of Biochemistry, University of Kassel, Kassel, Germany.

NPJ Parkinson'S Disease
|April 3, 2024
PubMed

Insights

Oxidation and reduction control the activity of leucine-rich repeat kinase 2 (LRRK2), a gene linked to Parkinson's disease (PD). This redox regulation offers potential therapeutic strategies for PD by downregulating LRRK2 kinase activity.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Structural Biology

Background:

  • Mutations in leucine-rich repeat kinase 2 (LRRK2) are linked to Parkinson's disease (PD).
  • LRRK2's kinase domain (KD) and GTPase domain harbor most pathogenic mutations.
  • A unique cysteine pair (CC motif) in LRRK2's Activation Segment (AS) is key to its function.

Purpose of the Study:

  • To elucidate the role of the LRRK2 CC motif (C2024, C2025) in modulating kinase activity.
  • To investigate the impact of redox modulation on LRRK2 function and microtubule binding.
  • To explore therapeutic potential of redox agents for LRRK2-associated PD.

Main Methods:

  • Site-directed mutagenesis to alter cysteine residues.
  • Biochemical assays to measure kinase activity.
  • Cell-based assays and Gaussian accelerated Molecular Dynamics (GaMD) simulations.
  • Treatment with reducing and oxidizing agents.

Main Results:

  • Cysteine 2024 (C2024) is essential for LRRK2 protein kinase activity.
  • Cysteine 2025 (C2025) significantly contributes to the redox sensitivity of LRRK2.
  • Oxidizing agents downregulate the kinase activity of LRRK2, particularly in PD-associated mutations.
  • GaMD simulations revealed redox state-dependent interactions of cysteines with surrounding residues.

Conclusions:

  • The CC motif in LRRK2 plays a critical role in regulating kinase activity via redox mechanisms.
  • Oxidizing agents represent a promising therapeutic avenue for targeting hyperactive LRRK2 in Parkinson's disease.
  • Understanding cysteine roles provides insights into LRRK2 regulation and PD pathogenesis.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.0K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

15.1K

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Protein Modifications in the RER01:26

Protein Modifications in the RER

Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.2K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.2K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K